Stay updated on Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial

Sign up to get notified when there's something new on the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The site footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-07T01:07:13.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    The access to the study record now loads a 403 Forbidden error, replacing the full content with an error screen. The page shows a simple message and a Home link instead of the detailed trial information.
    Difference
    17%
    Check dated 2026-09-23T00:56:02.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The revision label on the page was updated to v3.7.0, signaling a newer version of the page content. The previous revision, v3.6.6, was superseded by this update.
    Difference
    0.0%
    Check dated 2026-09-16T00:30:04.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    The page revision label changed from v3.6.5 to v3.6.6. This indicates a minor update to the page metadata without altering the displayed study details.
    Difference
    0.0%
    Check dated 2026-09-01T20:42:35.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    The page’s revision label was updated from v3.6.4 to v3.6.5, indicating a new revision of the page. This represents a maintenance/version update rather than a change to substantive content.
    Difference
    0.0%
    Check dated 2026-08-11T22:49:20.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    IPD sharing information was added to the study page, including an IPD Sharing URL and plan description. The update also introduces IPD sharing access criteria and related policy language, clarifying the availability of de-identified participant data to qualified researchers.
    Difference
    0.5%
    Check dated 2026-08-04T22:31:13.000Z thumbnail image

Stay in the know with updates to Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page.